5-氟尿苷 | 18814-21-6

• 物质功能分类: 生物化工 - 核苷类药物 - 核苷中间体
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 中文名称: 5-氟尿苷
• 英文名称: 5-Fluorouracil arabinoside
• 英文别名: 1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoropyrimidine-2,4-dione
• CAS: 18814-21-6；316-46-1；131-06-6
• 化学式: C₉H₁₁FN₂O₆
• 分子量: 262.19
• InChiKey: FHIDNBAQOFJWCA-UHFFFAOYSA-N

物化性质

• 熔点：
  182-184 °C
• 比旋光度：
  17 º (c=2, water 25 ºC)
• 密度：
  1.4200 (estimate)
• 溶解度：
  可溶于 DMSO（最高 50 mg/ml）、水（最高 50 mg/ml）或乙醇（加热最高 6 mg/ml）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  119
• 氢给体数：
  4
• 氢受体数：
  7

安全信息

• 储存条件：
  室温下，应密封保存，并保持干燥。

制备方法与用途

生物活性

5-氟尿啶（5-Fluorouridine）是5-氟尿嘧啶（5-fluorouracil）的代谢物，具有抗癌活性。研究显示，5-氟尿啶能够抑制人结肠癌细胞中rRNA的合成，并对L1210细胞表现出细胞毒性作用，其IC50值为2 nM。

用途

5-氟尿啶常作为抗肿瘤药物DFUR和FUDR生产的中间体，同时也广泛应用于基因工程和生化试剂等领域。

反应信息

• 作为反应物：
  描述：

  5-氟尿苷 以91的产率得到2',3'-O-Isopropylidene-5-fluorouridine
  参考文献：
  名称：

  Use of fosfluridine tidoxil (FT) for the treatment of intraepithelial proliferative diseases

  摘要：

  本发明涉及将Fosfluridine Tidoxil（5-氟尿嘧啶-5'-磷酸）（3-十二烷硫醇基-2-癸氧基）丙酯或其盐系统给药，用于治疗上皮内增生性疾病，如日光性角化症。Fosfluridine Tidoxil可以单独或与局部治疗药物联合进行系统给药。

  公开号：

  US20080014258A1

文献信息

• Modulators of DUX4 for regulation of muscle function
  申请人：GENEA BIOCELLS USA (HOLDINGS), INC.

  公开号：US10933068B2

  公开（公告）日：2021-03-02

  Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.

  本文公开了治疗面肱骨肌营养不良症和其他肌肉疾病或紊乱的方法和组合物。在某些情况下，这些方法和组合物涉及使用甲基转移酶抑制剂来抑制或抑制肌肉细胞中 DUX4 的表达。本文进一步公开了用于筛选治疗面阔肌营养不良症和其他肌肉疾病的化合物的方法和基于细胞的检测方法。
• Drug formulations for cancer treatment
  申请人：The Regents of the University of California

  公开号：US11191774B2

  公开（公告）日：2021-12-07

  Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.

  本文描述了含有这些化合物的化合物和药物制剂。还描述了制造和使用这些化合物的方法。这些化合物包括核碱基、核碱基类似物或其组合。在一个实施方案中，核碱基类似物与多柔比星结合并封装在脂质体中，用于抑制或防止癌细胞生长。进一步描述的是含有两种或两种以上治疗活性剂的药物组合物，这些活性剂封装在脂质体等囊泡内，其中活性剂的摩尔比可提供协同治疗效果。
• MODULATORS OF DUX4 FOR REGULATION OF MUSCLE FUNCTION
  申请人：GENEA BIOCELLS USA (HOLDING), INC.

  公开号：US20190298727A1

  公开（公告）日：2019-10-03

  Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.
• DRUG FORMULATIONS FOR CANCER TREATMENT
  申请人：The Regents of the University of California

  公开号：US20200306284A1

  公开（公告）日：2020-10-01

  Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.
• Modulators of DUX4 for Regulation of Muscle Function
  申请人：Sonic Master Limited

  公开号：US20210196723A1

  公开（公告）日：2021-07-01

  Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell-based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.

表征谱图